Novo Nordisk is exploring a new class of small molecule drugs that act as matchmakers between two proteins in partnership with a biotech startup called … ...
This story was updated to add new information. The parent company of Danish drug maker Novo Nordisk said it completed its $16.5 billion purchase of Catalent, including the Bloomington operations ...
Novo Nordisk, for its part, has been working hard to enrich its cardiometabolic pipeline in areas beyond diabetes and obesity, where the company currently dominates the commercial market with its ...
Dec 18 (Reuters) - Novo Holdings, the controlling shareholder of Novo Nordisk (NOVOb.CO), opens new tab, on Wednesday sealed its $16.5 billion deal for Catalent (CTLT.N), opens new tab ...
As a private company with Novo Holdings’ partnership and support, we are well-positioned to deliver unparalleled outcomes for our customers and the patients they serve, and ultimately create ...
COPENHAGEN, Dec 17 — Danish health authorities said on Monday they would ask the European Union’s drug regulator to review the findings of two Danish studies linking Novo Nordisk’s popular diabetes ...
Ozempic maker Novo Nordisk A/S took two large steps toward meeting demand for its blockbuster drugs, committing 8.5 billion kroner ($1.2 billion) to build a new factory in Denmark shortly after it ...
After clearing all regulatory hurdles associated with its proposed buyout of CDMO Catalent, Novo Holdings is nearly ready to unwrap its $16.5 billion present just in time for the holidays.
Medicinalvirksomheden regner med at skabe mindst 400 arbejdspladser. Medicinalgiganten Novo Nordisk tager mandag det første spadestik til anlægget af en ny fabrik ved Odense. I alt skal der ...
Novo Holdings will proceed with its $16.5 billion acquisition of Catalent, the companies announced Saturday, after the Federal Trade Commission decided not to challenge the deal. It’s expected to ...
Novos opkøb af Catalent ventes at falde på plads inden for få dage, efter de sidste godkendelser er klar. Novo Holdings har nu fået de sidste grønne lys til kæmpeopkøbet af den amerikanske ...
(Reuters) - All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had been fulfilled, the companies said on Saturday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback